Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.35 |
| ▸ | MAOB | P27338 | 4/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30256654 | 0.83 | NR1H2 (0.48) | S1PR1DDB1CRBNPPARA | |
| SCHEMBL23391717 | 0.78 | HDAC3 (0.33) | MAOAMAOBACHEASAH1HDAC3 | |
| SCHEMBL29547258 | 0.73 | MAOA (0.53) | MAOAMAOBACHEHDAC3HDAC2 | |
| SCHEMBL20581865 | 0.73 | MAOA (0.53) | MAOAMAOBACHEHDAC3HDAC2 | |
| SCHEMBL30754584 | 0.71 | NR1H2 (0.48) | TBXAS1SLC22A12 | |
| SCHEMBL23392066 | 0.71 | NR1H2 (0.48) | TBXAS1SLC22A12 | |
| SCHEMBL30256294 | 0.69 | NR1H2 (0.36) | HDAC3HDAC2HDAC6DDB1CRBN | |
| SCHEMBL23391716 | 0.69 | GABRG2 (0.38) | HDAC3HDAC2HDAC6 | |
| SCHEMBL20120376 | 0.68 | IRAK4 (0.37) | — | |
| SCHEMBL16268477 | 0.66 | HIPK2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117940167-A | Bifunctional molecules as proteasome stimulators for improved targeted protein degradation and their use as targeted enhancing degradation agents (TARBOD) | 博思德医疗科技有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20240091213-A1 | COMPOUNDS FOR TAU PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-03-21 | — | — | US | disclosed |
| EP-4310496-A2 | COMPOUNDS FOR TAU PROTEIN DEGRADATION | Dana-Farber Cancer Institute, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-3652329-B1 | COMPOUNDS FOR TAU PROTEIN DEGRADATION | DANA FARBER CANCER INST INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20210154184-A1 | COMPOUNDS FOR TAU PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240091213-A1 | COMPOUNDS FOR TAU PROTEIN DEGRADATION | UBQLN1, UBQLN2, CRBN | MAOA 1148/4885MAOB 1820/4885ACHE 344/4885 |
| US-20210154184-A1 | COMPOUNDS FOR TAU PROTEIN DEGRADATION | UBQLN1, UBQLN2, CRBN | MAOA 1148/4885MAOB 1820/4885ACHE 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.